Integra LifeSciences (NASDAQ:IART) Hits New 52-Week Low – Should You Sell?

Integra LifeSciences Holdings Corporation (NASDAQ:IART) reached a new 52-week low during mid-day trading on Friday . The stock traded as low as $10.60 and last traded at $11.33, with a volume of 1253512 shares traded. The stock had previously closed at $11.59.

Key Stories Impacting Integra LifeSciences

Here are the key news stories impacting Integra LifeSciences this week:

• Positive Sentiment: Beat on the headline numbers — adjusted EPS of $0.83 (vs. $0.79 consensus) and revenue of $434.9M (above ~$429.6M est.), driven by strength in the Codman Specialty Surgical segment. This gives some near‑term comfort on core surgical franchise performance. Integra LifeSciences (NASDAQ:IART) Surprises With Q4 CY2025 Sales
• Positive Sentiment: Analyst/coverage notes highlighted the quarter beat on both EPS and revenue, reinforcing that adjusted profitability and segment growth (neurosurgery, instruments, ENT) remain intact even as some product lines recover. Integra LifeSciences (IART) Beats Q4 Earnings and Revenue Estimates
• Neutral Sentiment: Management hosted an earnings call and provided the slide deck — useful for color on remediation progress, operational changes and the $25–$30M cost savings target for 2026 (simplified operating model). Listen/read the transcript for Q&A. Q4 2025 Earnings Call Transcript
• Neutral Sentiment: The company reiterated remediation and compliance progress (supply reliability improvements, product relaunches) which are operationally constructive but longer‑dated in impact. Press Release / 2025 Results & 2026 Guidance
• Negative Sentiment: Guidance disappointed near term — Q1 2026 adjusted EPS guide $0.37–$0.45 vs ~ $0.47 consensus, and Q1 revenue guide $375–$390M below the ~$393M street view. The softer Q1 guide is the main driver of the share decline. Integra beats estimates but guides below consensus
• Negative Sentiment: Balance‑sheet and cash concerns: net debt (~$1.6B), leverage ~4.5x, weak free cash flow conversion for 2025, and capital spending pressure — these constrain flexibility and amplify investor sensitivity to any misses. QuiverQuant summary of results
• Negative Sentiment: Large non‑cash items and legacy issues remain headline risks: FY2025 GAAP net loss driven by a $511M goodwill impairment and ongoing remediation/recall‑related charges — these limit the usefulness of GAAP EPS and keep upside tied to execution. Guidance also excludes potential tariff recoveries, adding uncertainty. MSN coverage: why stock trades down

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on IART. Wall Street Zen upgraded Integra LifeSciences from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. JPMorgan Chase & Co. boosted their target price on shares of Integra LifeSciences from $12.00 to $13.00 and gave the stock an “underweight” rating in a research report on Friday, October 31st. Truist Financial reaffirmed a “hold” rating and set a $13.00 price target (down from $15.00) on shares of Integra LifeSciences in a research note on Monday, November 3rd. Citigroup reduced their price objective on shares of Integra LifeSciences from $12.00 to $11.00 and set a “sell” rating for the company in a research note on Friday, October 31st. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Integra LifeSciences in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and three have given a Sell rating to the company. According to data from MarketBeat, Integra LifeSciences has a consensus rating of “Reduce” and an average price target of $15.00.

Integra LifeSciences Price Performance

The company has a debt-to-equity ratio of 1.73, a quick ratio of 1.80 and a current ratio of 3.14. The stock has a market capitalization of $882.49 million, a PE ratio of -1.75 and a beta of 1.04. The company’s fifty day simple moving average is $11.99 and its two-hundred day simple moving average is $13.20.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Thursday, February 26th. The life sciences company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.79 by $0.04. Integra LifeSciences had a negative net margin of 30.15% and a positive return on equity of 14.06%. The business had revenue of $434.93 million for the quarter, compared to analyst estimates of $429.62 million. During the same period in the prior year, the business earned $0.97 earnings per share. The company’s quarterly revenue was down 1.7% on a year-over-year basis. Integra LifeSciences has set its Q1 2026 guidance at 0.370-0.450 EPS and its FY 2026 guidance at 2.300-2.400 EPS. As a group, sell-side analysts predict that Integra LifeSciences Holdings Corporation will post 2.45 EPS for the current year.

Hedge Funds Weigh In On Integra LifeSciences

A number of institutional investors have recently made changes to their positions in IART. Global Retirement Partners LLC purchased a new stake in shares of Integra LifeSciences in the fourth quarter valued at $25,000. GAMMA Investing LLC increased its position in Integra LifeSciences by 55.3% during the 3rd quarter. GAMMA Investing LLC now owns 2,565 shares of the life sciences company’s stock worth $37,000 after purchasing an additional 913 shares in the last quarter. Osaic Holdings Inc. raised its stake in Integra LifeSciences by 36.6% in the 2nd quarter. Osaic Holdings Inc. now owns 4,119 shares of the life sciences company’s stock valued at $51,000 after purchasing an additional 1,104 shares during the last quarter. AlphaQuest LLC acquired a new position in Integra LifeSciences in the 2nd quarter valued at about $73,000. Finally, EMC Capital Management purchased a new position in Integra LifeSciences in the 2nd quarter valued at about $75,000. 84.78% of the stock is owned by institutional investors and hedge funds.

About Integra LifeSciences

Integra LifeSciences Corporation is a global medical technology company specializing in products and innovations for neurosurgery, regenerative medicine and reconstructive procedures. The company develops and markets surgical instruments, implants and advanced wound care solutions designed to support tissue repair and functional recovery. Its product portfolio includes collagen-based matrices, dural substitutes, hemostatic agents and specialized spinal and peripheral fixation devices.

Founded in 1989 and headquartered in Plainsboro, New Jersey, Integra has expanded its capabilities through targeted acquisitions and internal research efforts.